A Short Review on Recent Advances in Sensors for Cardiovascular Disease Markers in COVID-19 Management

Coronavirus 2019 (COVID-19) induced new cardiac pathologies and exacerbate underlying cardiovascular diseases. Cardiac biomarkers are frequently measured to provide guidance on the well-being of a patient in relation to cardiac health with many assays having been developed and widely utilised in clinical assessment. Effectively treating and managing cardiovascular disease (CVD) relies on swiftly responding to signs of cardiac symptoms, thus providing a basis for enhanced patient management and an overall better health outcome. Emerging biomarkers and corresponding sensors have the capacity to detect these markers along with design of nanomaterials has greatly assisted in the development of detection techniques that offer ultra-sensitive performances.